Evidence map›Paper›PMID 35241559›Full record

ArticleIn vivo (Athens, Greece)

Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.

Takafumi Nakano, Ryuji Yasumatsu, Kazuki Hashimoto, Ryosuke Kuga, Takahiro Hongo, Hidetaka Yamamoto, Mioko Matsuo, Takahiro Wakasaki, Rina Jiromaru, Tomomi Manako and 12 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

Takafumi Nakano *Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryuji Yasumatsu *Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; yasumatsu.ryuji.847@m.kyushu-u.ac.jp.
Kazuki HashimotoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryosuke KugaDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takahiro HongoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hidetaka YamamotoDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Mioko MatsuoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takahiro WakasakiDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Rina JiromaruDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tomomi ManakoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Satoshi TohDepartment of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
Muneyuki MasudaDepartment of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
Moriyasu YamauchiDepartment of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Yuichiro KuratomiDepartment of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Hideoki UryuDivision of Otorhinolaryngology and Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Torahiko NakashimaDivision of Otorhinolaryngology and Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Akihiro TamaeDepartment of Otolaryngology, Hamanomachi Hospital, Fukuoka, Japan.
Risa TanakaDepartment of Internal Medicine, Hamanomachi Hospital, Fukuoka, Japan.
Masahiko TauraDepartment of Otolaryngology Fukuoka University School of Medicine, Fukuoka, Japan.
Toranoshin TakeuchiDepartment of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Takamasa YoshidaDepartment of Otolaryngology, Sasebo Kyosai Hospital, Sasebo, Japan.
Takashi NakagawaDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyushu University · JPHamanomachi Hospital · JPNational Hospital Organization Kyushu Cancer Center · JPNational Kyushu Medical Center · JPSaga University · JPFukuoka University · JPKitakyushu Municipal Medical Center · JPSasebo City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimSurgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). PATIENTS AND

methodsWe retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis.

resultsEGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases.

conclusionOur results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.

Indexed as

CisplatinSalivary Gland NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabFluorouracilHumansNeoplasm Recurrence, LocalRetrospective StudiesCarboplatinCetuximabCisplatinFluorouracilcetuximabEGFRfluorescent in situ hybridizationimmunohistochemical stainnear-infrared photoimmunotherapySalivary gland caner

Identifiers

PMID35241559
PMCPMC8931902
OpenAlexW4214943765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.